@article {Hazan2021.09.02.21262832, author = {Sabine Hazan and Neil Stollman and Huseyin Bozkurt and Sonya Dave and Andreas J. Papoutsis and Jordan Daniels and Sibasish Dolai and Bradley D. Barrows and Eamonn MM Quigley and Thomas J. Borody}, title = {The missing microbes: Bifidobacterium and Faecalibacterium depletion and loss of microbiome diversity as potential susceptibility markers for SARS-CoV-2 infection and severity}, elocation-id = {2021.09.02.21262832}, year = {2021}, doi = {10.1101/2021.09.02.21262832}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objective To compare gut microbiome diversity and composition in SARS-CoV-2 polymerase chain reaction (PCR)-confirmed positive patients whose symptoms ranged from asymptomatic to severe versus PCR-negative exposed controls.Design Using a cross-sectional study design, we used shotgun next-generation sequencing (NGS) to evaluate microbiome composition and diversity in both patients with SARS-CoV-2 PCR-confirmed infections presenting to Ventura Clinical Trials for care from March 2020 through January 2021 and SARS-CoV-2 PCR-negative exposed controls. Patients were classified as being asymptomatic or having mild, moderate, or severe symptoms based on NIH criteria.1 Exposed controls were individuals with prolonged or repeated close contact with patients with SARS-CoV-2 infection or their samples, e.g. household members of patients or frontline healthcare workers. Microbiome diversity and composition were compared between patients and exposed controls and across patient subgroups at all taxonomic levels.Results There were 52 patients and 20 controls. Compared with controls, patients had significantly less bacterial diversity, a lower abundance of Bifidobacterium and Faecalibacterium as well as some other bacteria, and a higher abundance of Bacteroides at the genus level. Additionally, there was an inverse association between disease severity and both bacterial diversity and Bifidobacterium and Faecalibacterium abundance.Conclusion We hypothesize that low bacterial diversity and depletion of Bifidobacterium and Faecalibacterium genera either before or after infection led to reduced pro-immune function, thereby allowing SARS-CoV-2 infection to become symptomatic. This particular dysbiosis pattern may be a susceptibility marker for severe symptoms from SARS-CoV-2 infection and may be amenable to pre-, intra-, or post infection intervention.View this table:Competing Interest StatementSH and TJB have corporate affiliation to ProgenaBiome and Topelia therapeutics. AJP and BDB have corporate affiliations to Progenabiome. S Dave has corporate affiliation to McKesson Speciality Health and North End Advisory. S Dolai has corporate affiliation to Axent Medical and Topelia Therapeutics. SH and TJB have patents relevant to manuscript.Clinical TrialNCT04031469Funding StatementNo funding was received for this manuscript. Several authors were compensated or salaried by ProgenaBiome.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with ethical principles of the Declaration of Helsinki, the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP), and was approved by the Ethical and Independent Review Services (https://www.eandireview.com/) Independent Review Board (IRB). All patients provided written informed consent to participate in the study and the study is registered as clinicaltrials.gov NCT04031469.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available upon reasonable request from corresponding author, Dr. Sabine Hazan.}, URL = {https://www.medrxiv.org/content/early/2021/09/06/2021.09.02.21262832}, eprint = {https://www.medrxiv.org/content/early/2021/09/06/2021.09.02.21262832.full.pdf}, journal = {medRxiv} }